Wee1

Home Cell Cycle Wee1

Wee1 Products

  • All (6)
  • Wee1 Inhibitors (5)
  • New Wee1 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1525 Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Cancer Cell, 2025, 43(8):1530-1548.e9
Nat Cancer, 2025, 10.1038/s43018-025-00960-z
Cell Rep Med, 2025, S2666-3791(25)00102-8
Verified customer review of Adavosertib (MK-1775)
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.
iScience, 2025, 28(5):112292
Signal Transduct Target Ther, 2024, 9(1):181.
Nat Commun, 2024, 15(1):2089
F0602 Phospho-Wee1 (Ser642) Antibody [P3A10]
S9778 Debio 0123 WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.
J Clin Invest, 2025, 135(11)e188165
medRxiv, 2024, 2023.05.17.23290140
E1000 Azenosertib (Zn-C3) Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
bioRxiv, 2025, 2025.05.28.656693
medRxiv, 2024, 2023.05.17.23290140
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.
S1525 Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Cancer Cell, 2025, 43(8):1530-1548.e9
Nat Cancer, 2025, 10.1038/s43018-025-00960-z
Cell Rep Med, 2025, S2666-3791(25)00102-8
 Verified customer review of Adavosertib (MK-1775)
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.
iScience, 2025, 28(5):112292
Signal Transduct Target Ther, 2024, 9(1):181.
Nat Commun, 2024, 15(1):2089
S9778 Debio 0123 WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.
J Clin Invest, 2025, 135(11)e188165
medRxiv, 2024, 2023.05.17.23290140
E1000 Azenosertib (Zn-C3) Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
bioRxiv, 2025, 2025.05.28.656693
medRxiv, 2024, 2023.05.17.23290140
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.

Choose Selective Wee1 Inhibitors

Wee1Signaling Pathway

Wee1 signal pathway